No Trade Is Still a Decision

Alpha Intel investigated several major catalyst stocks without forcing a new trade.

GENC offered strong earnings, record backlog and a cash-rich balance sheet but failed final execution-quality tests.

ABCL offered an excellent clinical catalyst but had already undergone substantial same-day repricing.

NESR produced exceptional operating results but became extended.

SLN and REPL demonstrated why powerful catalysts cannot be evaluated independently of new share supply.

A PASS is not missing activity. It is an explicit decision that can later be graded.